Search Bar & Filters
Found 23 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of two drugs, inebilizumab and blinatumomab, in adults with active and treatment-resistant autoimmune diseases, including systemic lupus erythematosus SLE with nephritis and rheumatoid arthritis RA. This Phase 2 trial includes several subprotocols to study these medications in different patient groups and disease conditions. Participants may receive inebilizumab through intravenous infusions in either three or four doses, or blinatumomab via subcutaneous injections at low, medium, or high doses. The trial includes parts where doses are determined based on earlier results. The treatments are studied in subgroups of patients with SLE with or without nephritis and in patients with active refractory RA. Throughout the study, participants will be monitored for treatment-emergent adverse events and serious adverse events up to 52 weeks. Various clinical measures for kidney response, disease remission, and disease activity scores will be assessed at multiple time points. Safety, drug levels, antibody formation, and disease activity changes will be tracked regularly, with a total study duration extending up to 52 weeks for outcome evaluations.
Actively Recruiting
Researchers are evaluating DMX-200 repagermanium, a drug that blocks a receptor involved in inflammation, in patients with focal segmental glomerulosclerosis FSGS who are also receiving an angiotensin II receptor blocker ARB. This Phase 3 study aims to assess the safety and effectiveness of DMX-200 compared to placebo over two years in adults and adolescents aged 12 to 17 years. The study is led by Dimerix Bioscience Pty Ltd and includes a double-blind period followed by an open-label extension to observe long-term effects. Participants receive either 120 mg of DMX-200 or a matching placebo capsule twice daily for 104 weeks during the double-blind treatment phase. Afterward, those who complete this phase may enter a two-year open-label extension where all participants receive DMX-200 twice daily. The study includes a screening and qualification period lasting 6 to 14 weeks, a possible titration phase, a stabilization phase, and a follow-up period after treatments. Throughout the trial, patients will undergo assessments including urine proteincreatinine ratio and kidney function tests like estimated glomerular filtration rate eGFR at multiple time points up to week 104 and during the extension. Safety and tolerability are closely monitored through regular evaluations, adverse event tracking, and follow-up visits. Total participation may last about 230 weeks, covering all study phases and follow-up periods.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of three drugsfrexalimab, brivekimig, and rilzabrutinibin people aged 16 to 75 years who have primary focal segmental glomerulosclerosis FSGS or minimal change disease MCD. This Phase 2a, double-blind, placebo-controlled study aims to measure changes in proteinuria and how these drugs impact remission rates in nephrotic syndrome. Participants will be randomly assigned to one of six groups, receiving either frexalimab, brivekimig, rilzabrutinib, or a matching placebo. Treatment lasts 24 weeks, with the overall study duration up to 52 weeks. Participants will attend up to 16 visits during the study to receive the treatments and undergo assessments. Throughout the trial, participants will have their urine protein to creatinine ratio UPCR measured to assess treatment impact, particularly focusing on changes from baseline to Week 12. Other evaluations include tracking remission rates, monitoring for adverse events, and measuring drug concentrations and antibody responses up to Week 48. Participants will be closely monitored for safety and treatment effects during the study period.
Actively Recruiting
Researchers are evaluating the effects of felzartamab in adults with Immunoglobulin A nephropathy IgAN, a kidney disease caused by the buildup of abnormal IgA antibodies in the kidneys. This buildup leads to inflammation and damage, resulting in protein in the urine proteinuria. The study aims to learn how felzartamab affects proteinuria and kidney function compared to a placebo, while also assessing the safety and how the drug is processed by the body. Participants will be randomly assigned to receive either intravenous IV infusions of felzartamab or a placebo that contains no active medicine. The treatment period lasts for 24 weeks, followed by an 80-week follow-up period. Some participants with lower kidney filtration rates will be included in specific cohorts receiving either felzartamab or placebo. Overall, participants will have 17 study visits during about 2 years in the trial. During the study, participants will undergo various assessments including urine protein measurement, kidney function tests using estimated glomerular filtration rate eGFR, and monitoring for immune responses and adverse events. Blood samples will be collected to measure drug levels and antibodies against felzartamab. Safety will be monitored through vital signs, laboratory tests, physical exams, and ECGs. Researchers will evaluate changes from baseline up to 36 weeks for proteinuria and up to 104 weeks for kidney function and safety outcomes.
Actively Recruiting
Researchers are studying finerenone to find a better long-term treatment for children and young adults with heart failure and left ventricular systolic dysfunction LVSD, a condition where the hearts left side is weak and cannot pump blood well. The study aims to understand how safe finerenone is and how well it works when added to standard heart failure treatments in participants from newborns up to 18 years old. Participants will receive finerenone treatment for up to 9 months while continuing their usual heart failure care. The study includes children and young adults who joined an earlier finerenone trial and newly enrolled newborns under 6 months old with LVSD. Participants will attend at least six visits during the treatment period, where various health checks and tests will be done. During the study visits, researchers will measure vital signs, take blood samples, perform heart tests like electrocardiograms and echocardiograms, and ask about medication use and any medical problems. Parents or guardians of newborns and infants will provide feedback on how acceptable the study drug formulation is. After finishing treatment, participants will have a follow-up health check about one month later. The study will monitor safety by tracking medical problems and changes in potassium levels, blood pressure, and kidney function.
Actively Recruiting
Researchers are studying children with heart failure caused by left ventricular systolic dysfunction LVSD, a condition where the heart cannot pump enough blood. The goal is to see if the drug finerenone, which blocks a protein related to inflammation and scarring, can help the heart pump better compared to a placebo. This is the first study to test finerenone specifically in children with heart failure and LVSD, focusing on safety and effects on heart stress markers. Participants aged 6 months to under 18 years will be randomly assigned to receive either finerenone or a placebo for about three months, alongside their regular heart failure treatments. After this period, those who qualify may join an additional nine-month open-label phase where all receive finerenone. Those who do not join the extension will have a follow-up visit one month after finishing treatment. During the study, participants will visit the clinic at least three times for physical exams, heart tests including ECG and echocardiogram, blood tests, and measurements like blood pressure and heart rate. Researchers will track changes in a heart stress protein called NT-proBNP, monitor safety by recording any adverse events, and measure other heart function markers. The total study duration can be up to about a year including the extension and follow-up.
Actively Recruiting
Researchers are collecting clinical data to evaluate the ongoing safety and performance of commercially approved Biosense Webster Inc. BWI medical devices used during routine cardiac arrhythmia mapping and ablation procedures. This observational study aims to confirm the safety and effectiveness of these devices in real-world settings and expand knowledge about their use in treating cardiac arrhythmias such as atrial fibrillation, supraventricular tachycardia, and ventricular tachycardia. Participants diagnosed with cardiac arrhythmias who are scheduled for catheter ablation using BWI therapeutic catheters, including Varipulse Catheter and Dual Energy THERMOCOOL SMARTTOUCH SF Catheter, will be observed during their routine clinical care. No specific interventions are assigned by the study instead, participants undergo standard treatment with these devices as part of their medical management. During the study, participants will be monitored for adverse events related to the devices and procedures, both shortly after ablation and up to one year. Researchers will track arrhythmia outcomes and repeated procedures as part of routine follow-up. Data collection includes safety assessments, arrhythmia recurrence, and hospitalization events. Participation may last up to a year, with ongoing observation during routine healthcare visits.
Actively Recruiting
Researchers are conducting the Cardiovascular Outcomes Registry in Cardiogenic SHOCK COR-SHOCK, an observational study focused on adult patients admitted with cardiogenic shock. The study aims to evaluate how management strategies and clinical outcomes have changed over time, and how clinical, laboratory, and advanced hemodynamic monitoring relate to patient survival and prognosis. The registry captures detailed real-world data including laboratory tests and invasive hemodynamic measurements to understand the complex pathophysiology of cardiogenic shock. Participants receive standard medical care for cardiogenic shock as determined by their clinical team, with no experimental treatments involved. Data is collected retrospectively and prospectively from electronic health records, covering clinical, laboratory, imaging, and advanced hemodynamic parameters. The study includes a retrospective cohort from 2017 to 2025 and plans to recruit additional patients prospectively over 2 to 3 years, aiming for about 750 to 800 patients total. During the study, participants clinical data are collected and monitored up to one year after hospital admission to assess survival and clinical outcomes. Researchers perform quality assurance with data audits and source verification to maintain data accuracy. The primary outcome measured is all-cause mortality within 30 days of admission, with secondary outcomes including mortality at one year and major cardiovascular events. The study monitors participants through routine care without altering treatment and seeks to understand trends in management and outcomes over time.
Actively Recruiting
Researchers are evaluating a personalized prevention program PPP for people with stable coronary heart disease CHD who are at high risk of cardiovascular events. The study includes two parts Part A screens 12,000 stable CHD subjects using biomarkers to identify those at highest risk, while Part B is a randomized clinical trial comparing usual care to the PPP in 2,000 high-risk subjects. The goal is to assess the clinical value and cost-effectiveness of the PPP and validate risk biomarkers for predicting cardiovascular events. Participants in the PPP group will visit the study site six times over three years to receive lifestyle coaching, exercise prescriptions, and medication guidance following European Society of Cardiology guidelines. These activities are supported by digital tools called the CoroPrevention Tool Suite. The usual care group will continue receiving standard care from their physicians and have two study visits during the three years. Participants will undergo evaluations including biomarker measurements, behavioral assessments, questionnaires on nutrition and exercise, and monitoring of cardiovascular events. The study will track outcomes like cardiovascular death, heart attacks, and heart failure over three years. Researchers will also study the impact of behavioral changes, adherence to exercise and medication prescriptions, and the economic value of the prevention program. Safety and progress will be monitored throughout the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Myval Transcatheter Heart Valve THV Series compared to Contemporary Valves, including the Sapien THV Series and Evolut THV Series, in patients with severe symptomatic native aortic valve stenosis. This multinational, prospective, randomized trial involves 768 participants and aims to assess whether the Myval device performs at least as well as the other commercially available valves in improving heart valve function. Participants will be randomly assigned to receive either the Myval THV Series or one of the Contemporary Valves via a transfemoral approach. The Myval devices come in various sizes ranging from 20 mm to 29 mm, with additional registries for extra-large sizes. Separate study groups include a non-randomized nested registry for extra-large Myval devices and a lead-in set to ensure procedural adherence by investigators before enrolling subjects. During the study, participants will undergo assessments including clinical evaluations and imaging to monitor valve function and safety over time. Outcomes measured include a combined safety and effectiveness endpoint at 30 days, as well as longer-term monitoring for mortality, stroke, kidney injury, valve performance, and quality of life up to 10 years. The study involves follow-ups at multiple timepoints to comprehensively evaluate the devices performance and patient health.
1-10 of 23
1